Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.

Liu X. et al, (2023), The Journal of infection, 87, 18 - 26

Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].

Liu X. et al, (2023), The Journal of infection, 86, 540 - 541

Optimising the timing of whooping cough immunisation in mums (OpTIMUM) through investigating pertussis vaccination in pregnancy: an open-label, equivalence, randomised controlled trial.

Calvert A. et al, (2023), Lancet Microbe

Pneumococcal carriage following PCV13 delivered as one primary and one booster dose (1 + 1) compared to two primary doses and a booster (2 + 1) in UK infants.

Goldblatt D. et al, (2023), Vaccine

Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.

Shaw RH. et al, (2023), J Infect

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials

Voysey M. et al, (2023), Clinical and Experimental Immunology, 211, 280 - 287

Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: A multi-country prospective cohort study in Europe.

Mao Z. et al, (2023), Vaccine

Nasopharyngeal Carriage of Pneumococcus in Children in England up to 10 Years After 13-Valent Pneumococcal Conjugate Vaccine Introduction: Persistence of Serotypes 3 and 19A and Emergence of 7C

Tiley KS. et al, (2023), The Journal of Infectious Diseases, 227, 610 - 621

A Randomized Trial Assessing the Immunogenicity and Reactogenicity of Two Hexavalent Infant Vaccines Concomitantly Administered With Group B Meningococcal Vaccine.

Rajan M. et al, (2023), The Pediatric infectious disease journal, 42, 66 - 73

Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection

Mentzer AJ. et al, (2023), Nature Medicine, 29, 147 - 157

Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial

Shaw RH. et al, (2022), The Lancet Respiratory Medicine, 10, 1049 - 1060

The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study.

Wildenbeest JG. et al, (2022), The Lancet. Respiratory medicine

The emotional well-being of parents with children at genetic risk for type 1 diabetes before and during participation in the POInT-study.

Houben J. et al, (2022), Pediatric diabetes

Elevations in blood glucose before and after the appearance of islet autoantibodies in children.

Warncke K. et al, (2022), The Journal of clinical investigation, 132

An observational, cohort, multi-centre, open label phase IV extension study comparing preschool DTAP-IPV booster vaccine responses in children whose mothers were randomised to one of two pertussis-containing vaccines or received no pertussis-containing vaccine in pregnancy in England.

Sapuan S. et al, (2022), Vaccine

Differentiating vaccine reactions from invasive bacterial infections in young infants presenting to the emergency department in the 4CMenB era: a retrospective observational comparison.

Channon-Wells SW. et al, (2022), BMJ Paediatr Open, 6

Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector RSV Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV Seropositive Children 12-24 Months.

Stuart A. et al, (2022), The Journal of infectious diseases

Successful integration of newborn genetic testing into UK routine screening using prospective consent to determine eligibility for clinical trials

Bendor-Samuel OM. et al, (2022), Archives of Disease in Childhood

Clinical and Viral Factors Associated With Disease Severity and Subsequent Wheezing in Infants With Respiratory Syncytial Virus Infection.

McGinley JP. et al, (2022), The Journal of infectious diseases, 226, S45 - S54

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

Munro APS. et al, (2022), The Lancet Infectious Diseases, 22, 1131 - 1141

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?